Literature DB >> 30843622

Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.

Fresia Pareja1, Pier Selenica1, David N Brown1, Ana P M Sebastiao1, Edaise M da Silva1, Arnaud Da Cruz Paula1, Angela Del1, Li Fu2, Britta Weigelt1, Edi Brogi1, Jorge S Reis-Filho1, Hannah Y Wen1.   

Abstract

AIMS: Micropapillary variant of mucinous carcinoma of the breast (MPMC) is a rare histological form of oestrogen receptor (ER)-positive invasive carcinoma that is characterised by micropapillary clusters of tumour cells in lakes of extracellular mucin. The aims of this study were to determine the genetic alterations underpinning MPMCs, and to determine whether they overlap with those of mucinous carcinomas and/or invasive micropapillary carcinomas. METHODS AND
RESULTS: DNA from five MPMCs was subjected to whole-exome sequencing. Somatic mutations, copy number alterations and mutational signatures were determined with state-of-the-art bioinformatics methods. No mutations in genes significantly mutated in breast cancer, including TP53, PIK3CA, GATA3, and MAP3K1, were detected. We identified copy number alterations that have been reported in invasive micropapillary carcinomas, such as recurrent gains in 1q, 6p, 8q, and 10q, and recurrent losses in 16q, 11q, and 13q, as well as a recurrent 8p12-8p11.2 amplification encompassing FGFR1. Like mucinous carcinomas, three of the five MPMCs analysed lacked PIK3CA mutations, 1q gains, and 16q losses, which are the hallmark genetic alterations of ER-positive breast cancers, whereas two MPMCs harboured 16q losses and/or a complex pattern of copy number alterations similar to those found in breast-invasive micropapillary carcinomas.
CONCLUSIONS: MPMCs are heterogeneous at the genetic level; some tumours show a pattern of somatic genetic alterations similar to those of mucinous carcinomas, whereas others resemble invasive micropapillary carcinomas at the genetic level. These findings suggest that MPMCs may not constitute one histological subtype, but rather a convergent phenotype that can stem from mucinous carcinomas or invasive micropapillary carcinomas.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  breast cancer; massively parallel sequencing; micropapillary variant of mucinous carcinoma

Mesh:

Substances:

Year:  2019        PMID: 30843622      PMCID: PMC6591080          DOI: 10.1111/his.13853

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  25 in total

1.  Clinicopathological evaluation of 100 cases of mucinous carcinoma of breast with emphasis on axillary staging and special reference to a micropapillary pattern.

Authors:  Aditi Ranade; Rashmi Batra; Gagangeet Sandhu; Rohit A Chitale; Jasminka Balderacchi
Journal:  J Clin Pathol       Date:  2010-10-20       Impact factor: 3.411

2.  Genetic interactions in cancer progression and treatment.

Authors:  Alan Ashworth; Christopher J Lord; Jorge S Reis-Filho
Journal:  Cell       Date:  2011-04-01       Impact factor: 41.582

3.  CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia.

Authors:  Megan E McNerney; Christopher D Brown; Xiaoyue Wang; Elizabeth T Bartom; Subhradip Karmakar; Chaitanya Bandlamudi; Shan Yu; Jinkyung Ko; Barry P Sandall; Thomas Stricker; John Anastasi; Robert L Grossman; John M Cunningham; Michelle M Le Beau; Kevin P White
Journal:  Blood       Date:  2012-12-03       Impact factor: 22.113

4.  Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type.

Authors:  Britta Weigelt; Felipe C Geyer; Hugo M Horlings; Bas Kreike; Hans Halfwerk; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2009-07-24       Impact factor: 7.842

5.  Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast.

Authors:  C Marchiò; M Iravani; R Natrajan; M B Lambros; K Savage; N Tamber; K Fenwick; A Mackay; R Senetta; S Di Palma; F C Schmitt; G Bussolati; L O Ellis; A Ashworth; A Sapino; J S Reis-Filho
Journal:  J Pathol       Date:  2008-08       Impact factor: 7.996

6.  Mucinous micropapillary carcinoma of the breast: an aggressive counterpart to conventional pure mucinous tumors.

Authors:  Violetta Barbashina; Adriana D Corben; Muzaffar Akram; Christina Vallejo; Lee K Tan
Journal:  Hum Pathol       Date:  2013-03-19       Impact factor: 3.466

7.  Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.

Authors:  Magali Lacroix-Triki; Paula H Suarez; Alan MacKay; Maryou B Lambros; Rachael Natrajan; Kay Savage; Felipe C Geyer; Britta Weigelt; Alan Ashworth; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2010-11       Impact factor: 7.996

8.  Inactivating CUX1 mutations promote tumorigenesis.

Authors:  Chi C Wong; Inigo Martincorena; Alistair G Rust; Mamunur Rashid; Constantine Alifrangis; Ludmil B Alexandrov; Jessamy C Tiffen; Christina Kober; Anthony R Green; Charles E Massie; Jyoti Nangalia; Stella Lempidaki; Hartmut Döhner; Konstanze Döhner; Sarah J Bray; Ultan McDermott; Elli Papaemmanuil; Peter J Campbell; David J Adams
Journal:  Nat Genet       Date:  2013-12-08       Impact factor: 38.330

9.  Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.

Authors:  Rachael Natrajan; Paul M Wilkerson; Caterina Marchiò; Salvatore Piscuoglio; Charlotte K Y Ng; Patty Wai; Maryou B Lambros; Eleftherios P Samartzis; Konstantin J Dedes; Jessica Frankum; Ilirjana Bajrami; Alicja Kopec; Alan Mackay; Roger A'hern; Kerry Fenwick; Iwanka Kozarewa; Jarle Hakas; Costas Mitsopoulos; David Hardisson; Christopher J Lord; Chandan Kumar-Sinha; Alan Ashworth; Britta Weigelt; Anna Sapino; Arul M Chinnaiyan; Christopher A Maher; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2014-02-05       Impact factor: 7.996

10.  Comprehensive molecular portraits of human breast tumours.

Authors: 
Journal:  Nature       Date:  2012-09-23       Impact factor: 49.962

View more
  7 in total

1.  Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast.

Authors:  Peng Sun; Zaixuan Zhong; Qianyi Lu; Mei Li; Xue Chao; Dan Chen; Wenyan Hu; Rongzhen Luo; Jiehua He
Journal:  Mod Pathol       Date:  2020-05-01       Impact factor: 7.842

2.  New Insights into Tumor Heterogeneity: A Case of Solid-Oncocytic Epithelial-Myoepithelial Carcinoma of the Parotid Gland Harboring a HRAS and Heterogeneous Terminating ARID1A Mutation.

Authors:  Niels J Rupp; Muriel Brada; Alena Skálová; Beata Bode; Martina A Broglie; Grégoire B Morand; Markus Rechsteiner; Sandra N Freiberger
Journal:  Head Neck Pathol       Date:  2019-07-15

3.  The clinicopathological and prognostic characteristics of mucinous micropapillary carcinoma of the breast.

Authors:  Yangyang Sun; Wenxian Gu; Gengfang Wang; Xiaoli Zhou
Journal:  Histol Histopathol       Date:  2022-02-15       Impact factor: 2.130

Review 4.  Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2020-03-23

5.  Sonographic Features of Pure Mucinous Brelast Carcinoma With Micropapillary Pattern.

Authors:  Wu Zhou; Yong-Zhong Li; Li-Min Gao; Di-Ming Cai
Journal:  Front Oncol       Date:  2021-10-22       Impact factor: 6.244

Review 6.  Micropapillary Breast Carcinoma: From Molecular Pathogenesis to Prognosis.

Authors:  Georgios-Ioannis Verras; Levan Tchabashvili; Francesk Mulita; Ioanna Maria Grypari; Sofia Sourouni; Evangelia Panagodimou; Maria-Ioanna Argentou
Journal:  Breast Cancer (Dove Med Press)       Date:  2022-03-12

7.  Triple-Positive Breast Carcinoma: Histopathologic Features and Response to Neoadjuvant Chemotherapy.

Authors:  Jennifer Zeng; Marcia Edelweiss; Dara S Ross; Bin Xu; Tracy-Ann Moo; Edi Brogi; Timothy M D'Alfonso
Journal:  Arch Pathol Lab Med       Date:  2021-06-01       Impact factor: 5.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.